The immunosuppressive drugs Tocilizumab and Sarilumab improved survival and recovery time of intensive care of Covid-19 patients The UK government encourages (https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103134) the use of c and Sarilumab, medications initially developed to improve arthritis symptoms, to treat severe COVID-19 cases. The study, which has not yet been peer-reviewed, evaluating around 800 patients in intensive care […]
Tagged: Treatments
Arthritis Drugs for Critically Ill COVID-19 Patients
January 12th, 2021 | TreatmentsPromising news from drug combo for slowing ALS progression
September 29th, 2020 | TreatmentsCurrently, there are two approved drugs to treat ALS: Riluzole, which can extend lifespan by an average of a few months and has been on the market for 25 years Edaravone, approved in 2017, which in clinical trials showed to help patients function for longer into their disease. Unfortunately, ALS is still a deadly disease […]
FDA approved mesenchymal stem cell (MSC) treatments as compassionate use in the very sickest COVID-19 patients.
April 22nd, 2020 | TreatmentsA pilot study in China in which seven COVID-19 patients received intravenous infusions of donor mesenchymal stem cells (MSC) indicates that the intervention was safe, and that the approach may improve infection outcomes was reported in Aging and Disease last month. We understand that it is only a small number of cases, and studies in […]
Experience in rare disease and enzyme replacement treatment may help clinical plans for Parkinson’s disease: Lysosomal Dysfunction – A Parkinson’s-Gaucher Link?
January 17th, 2020 | TreatmentsWorldwide, over 4,000 patients with Gaucher disease have received enzyme replacement treatment (ERT), which is safe and well tolerated. Gaucher disease is a rare disease caused by mutations in GBA1. GBA1 mutations drive extensive accumulation of glucosylceramide (GC) in immune cells in the spleen, liver, lung and bone marrow. Extensive GC storage induces complement-activating IgG […]